Analyst Martin Auster works at CREDIT SUISSE and is focused on the Healthcare sector with 322 price targets and ratings documented since 2017 spanning on 23 stocks. Previously, Martin Auster worked at UBS. Analyst's average stock valuation to be materialised ratio is 57.86% with an average time for price targets to be met of 177.39 days.
Most recent stock forecast was given on BMRN, BioMarin Pharmaceutical Inc at 01-Jun-2022.
Martin Auster best performing recommendations are on SLDB (SOLID BIOSCIENCES INC).
The best stock recommendation documented was for SLDB (SOLID BIOSCIENCES INC) at 5/14/2019. The price target of $6 was fulfilled within 1 day with a profit of $0.32 (5.06%) receiving and performance score of 50.63.
Average potential price target upside